Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds
- Registration Number
- NCT00755989
- Lead Sponsor
- Banner Health
- Brief Summary
Morphine gel applied topically to wounds will reduce wound pain and decrease patients use of oral and intravenous pain medications, therefore reducing side effects.
- Detailed Description
Patients will be randomized to receive either placebo (versa base gel) or morphine gel to wound. Patients receiving morphine gel will have a decrease in pain score and use less oral/intravenous pain medications.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Signed and dated consent form & HIPAA
- > 18 yo
- Single stage 2-3 wound
- No allergy to morphine
- Alert and oriented (thinking ability clear and intact, physician approval)
- English language proficiency
Exclusion Criteria
- Allergy to morphine, codeine, or versa base, pts taking medications for acute condition, other than for the wound pain
- Patients with neuropathies
- Patients with respiratory conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 morphine topical gel Morphine gel 1 placebo group to receive topical gel without morphine
- Primary Outcome Measures
Name Time Method Safety and efficacy with the use of morphine gel applied topically for pain control 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Banner Good Samaritan Medical Center
🇺🇸Phoenix, Arizona, United States